Organisation paid for research Program year 2025 Source: CMS Open Payments

Carti

Neither a doctor nor a teaching hospital

Research payments

$356,177

33 payments

Through program year 2025, Carti is reported as receiving $356,177 in research payments, across 33 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $30,404 4
2024 Research $243,156 8
2023 Research $28,235 2
2022 Research $14,013 2
2021 Research $13,838 2
2020 Research $17,888 3
2019 Research $8,644 12

Breakdown

Who paid Research payments · program years 2019–2025
  1. Instylla Inc. $204,746 10 payments
  2. AstraZeneca UK Limited $97,050 4 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $45,738 7 payments
  4. Pfizer Inc. $7,900 2 payments
  5. Amgen Inc. $425 1 payment
  6. Incyte Corporation $319 9 payments
Studies the money was for Research payments · program years 2019–2025
  1. Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate $158,231 4 payments
  2. A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma $97,050 4 payments
  3. Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of the Instylla Hydrogel Embolic System (HES) Compared With Standard of Care Transcatheter Arterial Embolization (TAE) / Transcatheter Arterial Chemoembolization (cTACE) for Vascular Occlusion of Hypervascular Tumors; A Pivotal Study $46,515 6 payments
  4. A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - MM Study $27,850 4 payments
  5. A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the Insight - MM Study $17,888 3 payments
  6. Metastatic Renal Cell Cancer Reigstry Marcc Registry $7,900 2 payments
  7. Prospective Observational Study of Onpro vs SOC $425 1 payment
  8. Prospective, Non Interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic Or Community Clinical Practices $319 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record